Silent hyperlipidaemia modulated vascular endothelial markers

Background: belongs to the cytokine family IL-1. IL-18 is synthesized as inactive precursors which need to be processed into an active interleukin by the Caspase-1 enzyme. The role of IL-18 is implicated in several auto-immune disorders, myocardial function, emphysema, metabolic syndromes, psoriasis, bowel inflammation, sepsis, and acute kidney injury. IL-18 exhibits pro-inflammatory properties, such as increased cell adhesion molecules, nitric oxide production, enhancement of T-cell and natural killer cell maturation, and increasing the production of chemokines. This study was designed from November 2020 to February 2021 at Al-Shomali hospital, Babylon governorate, Iraq. This study aimed to assess the levels of IL-18 in patients with PCOS, T2DM and CAD before treatment with metformin and after metformin medication, and to evaluate the roles of IL-18 in the development of this disease. Materials and methods:The study design is a case-control study and patients are selected by simple randomization after diagnosis by a specialist based on clinical diagnosis and laboratory findings. An enzyme-linked immunosorbent test (ELISA) was used to estimate the level of serum IL-18 before and after metformin administration. A total of 300 patients were involved in this study, divided according to their chronic illness as 60 women with PCOS, 60 patients Type 2 diabetes mellitus (T2DM), 60 patients with myocardial infarction (MI), and 60 patients with T2DM and MI. In addition, 30 healthy people as a control group. Results: Before treatment with metformin, the results were exhibited a significant difference (P≤0.0001) in the concentrations of IL-18 in PCOS, T2DM, and patients with CAD as compared with control. While, after metformin treatment, a significant decrease (P≤0. 01, P≤0.0001 and P≤0.001) in IL-18 level in patients with PCOS and T2DM and CAD respectively as compared to before metformin treatment. Conclusion: Metformin administration reduces the inflammatory events of IL-18 in patients with T2DM and CAD and PCOS.

Section: Discussionmentioning

confidence: 91%

Metformin May Ameliorate Inflammatory Events of Il-18 in Some Inflammatory Conditions

Alzamily¹,

Obaid²,

Al-Azzawi³

2022

“…Chronic diseases represent a challenging when coexisted with COVID-19. Hyperlipidemia associated with upset of inflammatory and endothelial markers (12), hypertension increase the risk of cardiometabolic abnormalities (13), and glucose dysregulation upset normal metabolic homeostasis (14). Moreover, patient with chronic diseases are polypharmacy individual (15,16) due to using hypolipidemic, hypoglycemic, and hypotensive therapy.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Therapeutic Effects Of combined Hydroxychloroquine And azithromycine in Patients With Covid-19

Althanoon¹

2022

Introduction:Coronavirus pandemic is currently a global health concern with no established treatment guidelines. The aim of the present study was to determine the therapeutic effectiveness of hydroxychloroquine combined with azithromycin in patients with positive coronavirus disease 2019 (COVID-19) admitted to the hospital with severe dyspnea, as well as the incidence of occurrence of adverse effects.Methods: It was intended to utilize a retrospective clinical study of approximately 250 adult patients admitted to the ALSALAM Teaching Hospital in Mosul city with mild to moderate COVID-19 in order to evaluate treatment efficacy in combination with clinical and biochemical findings. Two groups were involved in the research. The first patient group consisted of 250 people who got hydroxychloroquine in conjunction with azithromycin, while the second untreated control group consisted of 100 individuals who received no medication as part of the research.Results: Baseline parameters (clinical and biochemical assays) did not vary substantially among the two groups. Patients in the treatment group were hospitalized at a rate of 30%, compared to 27% in the untreated control group (P<0.001). Between groups, there were no statistically significant changes in mortality, non-invasive oxygen demand, or hospitalization duration. Biochemical and Clinical outcomes were comparable between those receiving hydroxychloroquine with azithromycin and those do not receive any medication. Conclusion: This treatment regimen was shown to be not affective in mild to severe positve COVID-19 hospitalized patients and was associated with a small number of mild to moderate clinical adverse effects.

“…The progression of atherosclerosis is traditionally believed to be due to dyslipidemia. Major causes of cardiovascular disease (CVD) are myocardial infarction, stroke (related complications) and atherosclerosis, an inflammatory disease of the vascular system, since the incidence of risk factors is increasing in developing countries, such as obesity and diabetes (1). The global incidence of CVD is expected to increase and put a higher economic burden on health care systems around the world.…”

Section: Introductionmentioning

confidence: 99%

Influence of Coenzyme Q10 on Hyperlipidemia Induced in Mice

Hamed¹,

Al-Alsadoon²,

Shaban³

et al. 2022

Background and objectives: hyperlipidemia is the hallmark of cardiovascular diseases, namely hypertension, ischemic heart diseases, and strokes. Treatment should be satisfactory to tackle the lipid disorder and maintain the circulatory normal lipid profile. Many factors/cofactors coordinate to maintain lipid levels within normal to avoid subsequent hazards associated with hyperlipidemia. Coenzyme Q10 is a ubiquitous endogenous biomolecule that plays an important biological role in the lipid catabolic pathway. The goal of the study is to define the role of Coenzyme Q10 in hyperlipidemic mice model induced manually.Methods: to do so, a diet based hyperlipidemia state was induced in mice and they were distributed into different groups to conform with our study objectives. A Coenzyme Q10 treated group was compared to the negative control group and the positive control group was used as well.Results: The biochemical and histological outcomes declared that Coenzyme Q10 has important lipidreducing effects which are parallel or even superior to lipid reducing drugs (e.g. Rosuvastatin). Conclusion of the present study addressed the lipid-lowering properties of Coenzyme Q10 in a newly induced hyperlipidemia mouse model bestowing the use of Coenzyme Q10 as add-on adjuvant therapy in a high-risk group or as a monotherapy in a prophylactic group.